An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS)
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2018
At a glance
- Drugs Oritavancin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Acronyms ORKIDS
- Sponsors Melinta Therapeutics; The Medicines Company
- 12 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 12 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 12 Mar 2018 Planned number of patients changed from 60 to 52.